| Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers G Hripcsak, JD Duke, NH Shah, CG Reich, V Huser, MJ Schuemie, ... Studies in health technology and informatics 216, 574, 2015 | 549 | 2015 |
| Temporal pattern discovery in longitudinal electronic patient records GN Norén, J Hopstadius, A Bate, K Star, IR Edwards Data Mining and Knowledge Discovery 20 (3), 361-387, 2010 | 187 | 2010 |
| Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events GN Norén, A Bate, R Orre, IR Edwards Statistics in medicine 25 (21), 3740-3757, 2006 | 138 | 2006 |
| Suspected adverse drug reactions reported for children worldwide K Star, GN Norén, K Nordin, IR Edwards Drug safety 34 (5), 415-428, 2011 | 131 | 2011 |
| A statistical methodology for drug–drug interaction surveillance GN Norén, R Sundberg, A Bate, IR Edwards Statistics in medicine 27 (16), 3057-3070, 2008 | 121 | 2008 |
| vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues T Bergvall, GN Norén, M Lindquist Drug safety 37 (1), 65-77, 2014 | 103 | 2014 |
| Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery GN Norén, J Hopstadius, A Bate Statistical methods in medical research 22 (1), 57-69, 2013 | 103 | 2013 |
| Duplicate detection in adverse drug reaction surveillance GN Norén, R Orre, A Bate, IR Edwards Data Mining and Knowledge Discovery 14 (3), 305-328, 2007 | 95 | 2007 |
| Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase® RE Chandler, K Juhlin, J Fransson, O Caster, IR Edwards, GN Norén Drug safety 40 (1), 81-90, 2017 | 82 | 2017 |
| Large‐scale regression‐based pattern discovery: the example of screening the WHO global drug safety database O Caster, GN Norén, D Madigan, A Bate Statistical Analysis and Data Mining: The ASA Data Science Journal 3 (4 …, 2010 | 81 | 2010 |
| Good signal detection practices: evidence from IMI PROTECT AFZ Wisniewski, A Bate, C Bousquet, A Brueckner, G Candore, K Juhlin, ... Drug safety 39 (6), 469-490, 2016 | 71 | 2016 |
| Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank O Caster, K Juhlin, S Watson, GN Norén Drug safety 37 (8), 617-628, 2014 | 67 | 2014 |
| Temporal pattern discovery for trends and transient effects: its application to patient records GN Norén, A Bate, J Hopstadius, K Star, IR Edwards Proceedings of the 14th ACM SIGKDD international conference on Knowledge …, 2008 | 60 | 2008 |
| Impact of stratification on adverse drug reaction surveillance J Hopstadius, GN Norén, A Bate, IR Edwards Drug safety 31 (11), 1035-1048, 2008 | 55 | 2008 |
| A hit-miss model for duplicate detection in the WHO drug safety database GN Norén, R Orre, A Bate Proceedings of the eleventh ACM SIGKDD international conference on Knowledge …, 2005 | 47 | 2005 |
| Earlier discovery of pregabalin’s dependence potential might have been possible O Caster, IR Edwards, GN Norén, M Lindquist European journal of clinical pharmacology 67 (3), 319-320, 2011 | 45 | 2011 |
| Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest RD Boyce, PB Ryan, GN Norén, MJ Schuemie, C Reich, J Duke, ... Drug safety 37 (8), 557-567, 2014 | 44 | 2014 |
| Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system GN Norén, T Bergvall, PB Ryan, K Juhlin, MJ Schuemie, D Madigan Drug safety 36 (1), 107-121, 2013 | 40 | 2013 |
| Modern methods of pharmacovigilance: detecting adverse effects of drugs GN Norén, IR Edwards Clinical medicine 9 (5), 486, 2009 | 39 | 2009 |
| Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance GN Norén, O Caster, K Juhlin, M Lindquist Drug safety 37 (9), 655-659, 2014 | 38 | 2014 |
Andrew BateGSK, LSHTM, NYUGeverifieerd e-mailadres voor gsk.com
